logo
welcome
Reuters

Reuters

Health

Health

Bluebird bio to be taken private by Carlyle and SK Capital amid cash crunch

Reuters
Summary
Nutrition label

79% Informative

Gene therapy maker Bluebird bio said on Friday it would be taken private by Carlyle and SK Capital Partners .

The investment firms have also offered an additional $6.84 per share, contingent upon achieving certain sales milestones, which represents a payment of about $66.48 million .

Under the agreement, bluebird stockholders will receive $ 3 per share in cash.

VR Score

89

Informative language

95

Neutral language

60

Article tone

formal

Language

English

Language complexity

50

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links